Clinical trials: Open Wound
Hypoparathyroidism, Osteoporosis
Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
The purpose of this study is to characterize and compare the pharmacokinetics of hPTH(1 34) after treatment with modified oral formulations (EBP11, EBP11-F1, EBP11-F2, EBP11-F4, EBP11-F5 and EBP22) versus three dose levels of…
- Conditions
- Hypoparathyroidism, Osteoporosis, Fractures, Bone, Other Disease
- Trial name
- NCT05965167
- Testing
- EBP05, Forteo 0.02 mg, EBP11
- Where
- Israel
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Entera Bio Ltd.
Trauma-related Wound, Surgical Incision
3M™ Topical Tissue Adhesive Versus Commercially Available Tissue Adhesive for the Closure of Lacerations and Incisions
The purpose of this study is to generate safety and performance data for 3M™ Topical Tissue Adhesive. Enrolled subjects with qualifying trauma lacerations or surgical incisions will be randomized to receive 3M™ Topical Tissue…
- Conditions
- Trauma-related Wound, Surgical Incision, Surgical Wound, Laceration
- Trial name
- Lublin (NCT06217081)
- Testing
- 3M Topical Tissue Adhesive, Histoacryl® Blue Topical Skin Adhesive
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Solventum US LLC
Effect of Test Articles on the Healing of a Wound Artificially Induced by Liquid Nitrogen Spray
Study to Determine if Fibrin Affects the Ability of a Wound to Heal
The objective of this study is to evaluate the potential inhibitory effects of HP802-247 Vehicle on wound closure (healing), by comparing mean days to closure of superficial (partial-thickness) thermal wounds against similar…
- Trial name
- NCT01253135
- Testing
- Fibrin, White Petrolatum
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Healthpoint
Acute Lung Injury (ALI) Associated With COVID-19, Inflammatory Lung Conditions Associated With COVID-19
First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
This is a phase 1 study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics of single (Part A and B) and multiple (Part B) doses of inhaled TD-0903.
- Trial name
- NCT04350736
- Testing
- TD-0903
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma